Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Merck & company, inc. symbols : FNCTF save search
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.13%
H: 0.4%
C: -0.06%
ylynk-006 keytruda lung merck update cancer cell trial plus
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
Published: 2023-12-07 (Crawled : 18:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.04%
H: 0.01%
C: -1.61%
ylynk-008 keytruda lung merck cancer cell trial plus
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease
Published: 2023-10-10 (Crawled : 11:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.17%
H: 0.13%
C: -0.68%
disease congress merck cancer pipeline research
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-24 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 1.28%
H: 0.0%
C: 0.0%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.31%
H: 0.96%
C: -1.35%
lynparza japan approved cancer treatment plus
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Published: 2023-06-01 (Crawled : 12:20) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.23%
H: 0.84%
C: 0.24%
lynparza fda cancer treatment plus
Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
Published: 2023-05-15 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.0%
H: 0.51%
C: -0.66%
merck asco pipeline treatment research meeting
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Published: 2023-03-02 (Crawled : 16:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 1.68%
H: 0.0%
C: 0.0%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.02%
H: 0.7%
C: 0.36%
lynparza treatment review update cancer
Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
Published: 2023-02-24 (Crawled : 13:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.45%
H: 0.21%
C: -0.18%
application authorization update
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19
Published: 2023-02-21 (Crawled : 22:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.57%
H: 0.9%
C: 0.16%
covid-19 trial update
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
Published: 2023-02-16 (Crawled : 16:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 7.92%
H: 0.0%
C: 0.0%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.8%
H: 0.6%
C: -0.29%
propel symposium trial results
Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference
Published: 2023-01-24 (Crawled : 11:00) - nutriband.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.27%
H: 0.1%
C: 0.1%
NTRB | $3.56 -8.76% 3.4K
|
Manufacturing
|
| O: -2.85%
H: 0.0%
C: -1.76%
RANI | $6.87 2.69% 2.62% 140K
|
|
| O: -1.1%
H: 1.91%
C: -3.82%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.11%
H: 0.0%
C: -1.35%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: -0.86%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: 0.0%
conference transdermal
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
Published: 2022-12-21 (Crawled : 13:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.35%
H: 0.99%
C: 0.92%
lynparza treatment approved cancer prostate cancer
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
Published: 2022-12-15 (Crawled : 12:20) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -1.17%
H: 0.48%
C: -0.55%
lynparza treatment review update cancer prostate cancer
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
Published: 2022-09-22 (Crawled : 11:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 5.36%
H: 0.0%
C: -1.08%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.02%
H: 4.26%
C: 3.5%
lynparza treatment approved china cancer ovarian cancer
Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
Published: 2022-08-29 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.48%
H: 0.19%
C: -1.4%
cancer
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
Published: 2022-08-16 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.71%
H: 1.04%
C: 0.7%
lynparza fda drug application grants review cancer submission prostate cancer
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
Published: 2022-08-04 (Crawled : 11:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -2.17%
H: 0.42%
C: 0.42%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.22%
H: 0.09%
C: -1.13%
lynparza treatment approved cancer her2- her2
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
Published: 2022-06-27 (Crawled : 11:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: 0.62%
H: 0.0%
C: -0.35%
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: -0.16%
H: 2.7%
C: 1.3%
lynparza treatment chmp positive cancer her2- her2
Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)
Published: 2022-05-10 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.82%
H: 1.33%
C: -0.35%
keytruda asco
Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo
Published: 2022-04-01 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M
|
Health Technology
|
| O: 0.17%
H: 1.69%
C: 1.62%
treatment sars-cov-2 molnupiravir lagevrio
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.